Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer.

Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

AA reported receiving personal fees for attending advisory from Bristol-MyersSquibb, 10.13039/100011338AstraZeneca, 10.13039/100004337Roche, 10.13039/100004319Pfizer, 10.13039/100009947Merck Sharp and Dohme, 10.13039/100004324Astella, 10.13039/100004312Eli Lilly, and 10.13039/100001003Boehringer-Ingelheim and receiving fees for speaking bureau for Eli Lilly, AstraZeneca, MSD for work performed outside of the current study. NM is a founder and minority shareholder of MaxiVAX SA, a private biotech company based in Geneva, Switzerland, working on personalized cancer immunotherapy and infectious disease vaccines, with no impact on the current manuscript. PS reported receiving grant from the Biomedical Advanced Research and Development Authority outside of this work. All other co-authors reported no competing interests.